Cervical Adenosquamous Carcinoma
Associated Genetic Biomarkers
NCI Definition: An uncommon carcinoma arising from the cervix. It is composed of malignant glandular epithelial cells and malignant squamous epithelial cells. 
There are 13 clinical trials for cervical adenosquamous carcinoma, of which 13 are open and 0 are completed or closed. Of the trials that contain cervical adenosquamous carcinoma as an inclusion criterion, 2 are phase 1 (2 open), 4 are phase 1/phase 2 (4 open), 4 are phase 2 (4 open), and 3 are phase 3 (3 open).
Bevacizumab, carboplatin, and paclitaxel are the most common interventions in cervical adenosquamous carcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.